PhorMed
Phase 2We are a biopharmaceutical company focused on the development and commercialization of RP-323, a targeted, cell repair, immunotherapy, that promotes the reduction of inflammation for treating neurological diseases, cancer, and such inflammatory lung disorders as Acute Respiratory Distress Syndrome (ARDS).
Founded
2018
Focus
Small Molecules
About
We are a biopharmaceutical company focused on the development and commercialization of RP-323, a targeted, cell repair, immunotherapy, that promotes the reduction of inflammation for treating neurological diseases, cancer, and such inflammatory lung disorders as Acute Respiratory Distress Syndrome (ARDS).
Company Info
TypePrivate
Founded2018
LocationCambridge, United States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile